Märkte
US Markets Slide as Oil Hits $98; Novartis Plunges Toward Record Loss
Brent crude climbs toward $100 on Middle East tensions, weighing on Wall Street and Switzerland's SMI. Novartis falls nearly 10% after Phase III trial miss, wiping out roughly CHF 24 billion in market value.
US Markets Mixed After Holiday; Oil Weighs on Sentiment as Novartis Plunges
Dow futures sink 0.8% as Brent crude approaches $100; Novartis shares tumble over 9% after second clinical miss hits Swiss index.
Dax slips as Brent crude nears $100 and oil prices pressure German stocks
The Dax fell to 25,975 in early afternoon trade as Brent crude approached $100 and WTI and European gas prices rose, while stock-specific ratings drove moves in Dax and MDax names.
US Stocks Expected to Open Mixed After Holiday; Oil Prices Pressuring Sentiment; SMI Continues Decline; Novartis Targets Record Daily Loss
US stock indices show slight movements before market open; oil prices rise, fueling concerns over rising interest rates; Swiss Market Index (SMI) continues to fall; Novartis shares plunge, potentially setting a record daily loss.
European Gas At 3-Year Highs: Winners and Losers in the Energy Crunch
Rising gas and fuel prices reshape European equity markets, boosting energy and shipping while weighing on industrials and automakers.
Novartis trial miss drags Swiss SMI lower; Nestlé, Ascom gain
Novartis shares fell nearly 10% after Del-desiran missed a Phase III endpoint, pulling the SMI lower while Nestlé, Sandoz and Ascom gained and Brent approached $100.
European stocks flat; Novartis plunge weighs on Switzerland's SMI
Markets held steady as high energy prices and inflation fears kept investors cautious, while a failed drug trial sent Novartis shares tumbling nearly 9%, dragging the Swiss SMI down more than 1%.
European Stocks Stay Flat; Novartis Study Flop Weighs on Swiss SMI
EuroStoxx 50 flat as high oil and gas prices persist. The Swiss SMI drops 1.18% while Novartis shares fall over 9% after a failed drug trial sinks the stock.
Novartis Plunges After Failed Muscle-Disease Trial; SMI Slides 1.3%
Novartis tumbled nearly 10% after its del-desiran candidate missed a Phase III primary endpoint, erasing roughly CHF 24 billion in market value and pulling the SMI lower. Nestlé and Roche helped stem the damage.
Swiss SMI opens lower as Novartis slides over 10% on trial setbacks; Nestlé leads gains
Novartis shares fell more than 10% to CHF 112.54 after missing primary endpoints in two late‑stage studies, dragging the SMI down 1.4%. Nestlé rose 2% while copper hit a record $14,533 a tonne.
European Stocks Fall as Crude Oil Holds Above $90 on Iranian Threats
Brent crude extends gains past $90 on Persian Gulf supply risks, compounding euro-area inflation pressure ahead of the ECB's expected rate hike.
Copper Hits Record as Novartis Drops on Study Miss; SMI Expected Lower
Copper surged to an all-time high above $14,500 a tonne on supply fears, while Novartis sank 5.2% pre-market after a failed muscle-disease study. The SMI was expected to open down.
Swiss Re shares drop 3.6% after Monte Carlo risk warning
The insurer fell to CHF 137.70 on Monday following comments at the industry’s Rendez‑Vous de Septembre meeting about rising reinsurance risks, while dividend yield remains at 4.4%.
European chip stocks rise on AI demand as Infineon gets Warburg buy
Infineon rose nearly 7% after Warburg upgraded it to Buy with a 84-euro target, while UBS lifted memory-chip revenue forecasts to $1.65 trillion by 2027.
European stocks little changed ahead of ECB decision and US inflation data
European equities were little moved Monday as investors awaited the ECB decision and US inflation data; oil shares rose on Gulf tensions while the SMI fell on Novartis and Swiss Re.
DAX slips 0.15% to 26,006 as Brent holds above $97, ECB rate hike expected
Germany's blue‑chip index fell 0.15% to 26,006.53 points, staying just above the 26,000 threshold, while Brent crude traded above $97 per barrel and markets price an ECB rate rise to 2.5%.
SMI falls 0.8% as Novartis and Swiss Re lead losses
Switzerland's benchmark index closed at 14,279 after Novartis and Swiss Re weighed, while ABB, Kühne+Nagel and semiconductor suppliers offset some declines.
Mirabaud sees Swiss equities as global niche leaders, not just defensive
Daniele Scilingo sees Swiss stocks as global niche leaders, warns AI valuations are stretched, and points to compounders, China adaptation, pharma innovation and UBS.
EuroStoxx 50 slides 0.8% as oil price rise fuels inflation fears
The Euro Stoxx 50 fell to 6,368.98, its lowest since early August, as higher oil prices and heightened Iran tensions revived inflation concerns and expectations of an ECB rate hike. Swiss and UK indices also moved modestly.
EuroStoxx 50 Rises 0.32% to 6,382.59 as Media Leads, Luxury Lags
European equities posted modest gains on Thursday, buoyed by hawkish comfort from Fed's Waller. Media stocks surged on a PepsiCo deal; luxury names slipped on weak China signals.
Swiss Life Reports Strong First-Half 2026 Results, Fee Growth and Cost Cuts Ahead
Swiss Life Holding AG reported a 8% increase in net profit and fee revenue in the first half of 2026, while outlining plans to cut 600 jobs by year-end 2028.
Why Is the Swiss Franc So Strong — and What Does It Mean for Switzerland?
The Swiss franc has a reputation that extends far beyond the borders of Switzerland.
Understanding Leverage in CFD Trading: Opportunity and Risk
Leverage allows traders to open positions larger than their actual account balance by borrowing capital from a broker. In CFD trading, leverage ratios can range widely depending on the asset class, the broker, and the…
Gold or Swiss Franc? How Two Safe Havens Behave in Times of Crisis
When financial markets become nervous, two names frequently return to the conversation: gold and the Swiss franc.
Swiss SMI slides over 1%, LVMH hits six‑year low, ABB leads gains
The Swiss market index fell to 14,221 as LVMH reached its lowest level since 2018, while ABB posted the biggest rise; USD/CHF slipped to 80.89 Rappen and US exchanges stayed closed for a holiday.